Esposito Pamela 4
4 · Kymera Therapeutics, Inc. · Filed Mar 20, 2026
Research Summary
AI-generated summary of this filing
Kymera (KYMR) Director Pamela Esposito Exercises Options, Sells Shares
What Happened
Pamela Esposito, a director of Kymera Therapeutics (KYMR), exercised stock options and sold shares on March 20, 2026. She acquired 2,500 shares by exercising options at $49.10 per share (cost = $122,750). On the same day she sold a total of 2,500 shares in the open market for aggregate proceeds of approximately $197,877 (three sale lots). The filing also shows a disposition of 2,500 shares at $0.00 associated with an option exercise (see context below). The sales were executed under a pre-established Rule 10b5-1 trading plan.
Key Details
- Transaction date: March 20, 2026. Transaction codes: M = option exercise, S = open-market sale.
- Option exercise (acquired): 2,500 shares @ $49.10 — total cost $122,750.
- Option-related disposition (reported at $0.00): 2,500 shares (likely net share settlement/withholding).
- Open-market sales (total 2,500 shares, proceeds ≈ $197,877):
- 700 shares, weighted avg $77.71 (sales prices ranged $77.46–$77.98) — proceeds $54,398.
- 600 shares, weighted avg $79.24 (range $78.70–$79.63) — proceeds $47,546.
- 1,200 shares, weighted avg $79.94 (range $79.73–$80.27) — proceeds $95,933.
- Footnotes: Trades were effected under a Rule 10b5-1 plan (Sept 17, 2025). The option shares were fully vested and exercisable. The filing provides weighted-average sale prices and commits to disclose per-share breakdown upon request.
- Shares owned after the transactions: not specified in this Form 4.
- Filing timeliness: report filed March 20, 2026 (same-day reporting; not indicated as late).
Context
- Code M indicates option exercise. The $0.00 disposition commonly reflects shares withheld or surrendered to cover taxes or exercise obligations (a net settlement), not a market sale. Separately, the reported open-market sales were planned under a 10b5-1 program, which is a pre-arranged trading plan that can limit the informational value of the sales as a signal.
- For retail investors: exercises show the insider converted options into stock (and may retain or sell some shares); sales under a 10b5-1 plan are often routine. This filing records a mix of exercise and sales, with net cash received from market sales exceeding the cash paid to exercise the reported lot.
Insider Transaction Report
Form 4
Esposito Pamela
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-20$49.10/sh+2,500$122,750→ 2,500 total - Sale
Common Stock
[F1][F2]2026-03-20$77.71/sh−700$54,398→ 1,800 total - Sale
Common Stock
[F1][F3]2026-03-20$79.24/sh−600$47,546→ 1,200 total - Sale
Common Stock
[F1][F4]2026-03-20$79.94/sh−1,200$95,933→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-03-20−2,500→ 0 totalExercise: $49.10Exp: 2031-06-15→ Common Stock (2,500 underlying)
Footnotes (5)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.46 to $77.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.70 to $79.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.73 to $80.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The shares underlying this stock option are fully vested and exercisable.
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact|2026-03-20